Immunovant, Inc. (IMVT) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
the bull case· 3
5
disclosed supplier and customer ties in SEC filings
sec filingsedgar4
funds on file reporting a position in the company
n-portas of Jun 30 '26225
managers reporting a position in thirteen f filings
13fJun 30 '26the bear case· 4
10 of 23
largest reporting managers that cut their stake in the latest quarter
13fJun 30 '26−2.02%
change in shares held by the ten largest reporting managers
13fJun 30 '2620
managers whose positions together make up four fifths of reported value
13fJun 30 '260.92%
largest weight within the State Street biotech ETF asset mix
n-portJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 3 '26 report. Not a forecast, not advice.
Of the 6 companies Immunovant, Inc. moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 2836, Biological Products, (No Diagnostic Substances), from each company's own filings. Largest first.
High 37.75 at 7:00 am ET, low 36.83 at 2:00 pm ET.
Immunovant, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
IMVT (Immunovant, Inc.) has 5 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
225 managers report a position worth $4.3B between them, and 20 of them hold 80% of it.
tall tick = annual report · 1 on record